Liva Pharmaceuticals receives approval from the USFDA for Haloperidol Decanoate Injection

Press Release Liva Pharmaceuticals receives approval from the USFDA for Haloperidol Decanoate Injection ------------------------------------------------------------------------------------------------ Ahmedabad, October 24, 2019 Liva Pharmaceuticals Limited, a wholly- owned subsidiary company of Cadila Healthcare Limited has received the approval from the USFDA for Haloperidol Decanoate Injection, 50 mg (base)/mL and 100 mg (base)/mL, single -dose vials , 250 mg (base)/5 mL (50 mg (base)/mL) and 500 mg (base)/5 mL (100 mg (base)/mL), multiple-dose vials (US RLD – Haldol Decanoate Injection, 50 mg (base)/mL and 100 mg (base)/mL). It will be manufactured at Liva Pharma’s manufacturing facility at Vadodara. Haloperidol is used in the trea tment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome. The group now has 274 approvals and has so far filed over 36 0 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 24,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗